The Scientific business of Thomson Reuters has announced that the Foundation for Biomedical Research and Innovation (FBRI) has selected its key intellectual property and pharmaceutical & life sciences data platforms - Thomson Innovation, Thomson Pharma and IDRAC - for a major national project. The project aims to accelerate translational research from academic research to clinical research and enhanced clinical care for the greater benefit of patients in Japan.
The project entitled 'Coordination, Support and Training Program for Translational Research' will be funded over three years by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan. The project fund, in turn, was allocated by the Japan Science & Technology Agency (JST) in support of the government's decade-long basic science and technology policy to bridge academic research and industrial expertise on applying basic research into practical clinical outcomes that can widely benefit patients in terms of improved medical care.
The national translational research project involves nine universities and a research institute. These include Tohoku University, University of Tokyo, Kyoto University, Osaka University, Kyushu University, Hokkaido Organization for Translation Research which comprises Hokkaido University, Asahikawa Medical College Medical College, Sapporo Medical University, and FBRI.
In November 2008, the Thomson Innovation user interface was launched in Japanese to enhance productivity and decision making for Japanese intellectual property (IP) professionals. Japan remains the worldwide leader in published patents according to data analysis of Derwent World Patent Index, the world's most comprehensive database of enhanced patent documents.
